These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 29195713)
41. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. Ombeni W; Kamuhabwa AR J Int Assoc Provid AIDS Care; 2016; 15(2):164-71. PubMed ID: 26514630 [TBL] [Abstract][Full Text] [Related]
42. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898 [TBL] [Abstract][Full Text] [Related]
44. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
45. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon. Abongwa LE; Nyamache AK; Charles F; Torimiro J; Emmanuel N; Domkam I; Eyongetah M; Jude B; Mua FH; Bella S; Tamboh TC; Moungang EC; Ngum V; Okemo P BMC Gastroenterol; 2022 Jun; 22(1):286. PubMed ID: 35658835 [TBL] [Abstract][Full Text] [Related]
46. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
47. Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program. Paengsai N; Noppakun K; Jourdain G; Cressey TR; Salvadori N; Chaiwarith R; Tantraworasin A; Mary JY; Bowonwatanuwong C; Bhakeecheep S; Traisathit P; Kosachunhanun N Healthcare (Basel); 2022 Aug; 10(8):. PubMed ID: 36011147 [TBL] [Abstract][Full Text] [Related]
48. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
49. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050 [TBL] [Abstract][Full Text] [Related]
50. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H; Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492 [TBL] [Abstract][Full Text] [Related]
51. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia. Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306 [TBL] [Abstract][Full Text] [Related]
52. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473 [TBL] [Abstract][Full Text] [Related]
53. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. Flandre P; Pugliese P; Allavena C; Katlama C; Cotte L; Cheret A; Cabié A; Rey D; Chirouze C; Bani-Sadr F; Cuzin L; HIV Med; 2016 May; 17(5):380-4. PubMed ID: 27093565 [TBL] [Abstract][Full Text] [Related]
54. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228 [TBL] [Abstract][Full Text] [Related]
55. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564 [TBL] [Abstract][Full Text] [Related]
56. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW; J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392 [TBL] [Abstract][Full Text] [Related]
58. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. Sreenivasan S; Dasegowda V J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454 [TBL] [Abstract][Full Text] [Related]
59. Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis. Sun J; Liu L; Shen J; Qi T; Wang Z; Song W; Zhang R; Lu H PLoS One; 2015; 10(7):e0133242. PubMed ID: 26207639 [TBL] [Abstract][Full Text] [Related]
60. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]